Metabolic Oncology

A 2026 narrative review in Pharmaceuticals (MDPI, DOI: 10.3390/ph19020297) maps semaglutide's pleiotropic effects onto two domains relevant to performance practitioners: oncogenic signalling risk and mitigation of chemotherapy-driven cardiotoxicity. The net oncogenic signal is confounded by obesity itself; the cardiotoxicity mitigation data are preclinical but mechanistically precise. Both domains alter risk stratification for specific user profiles.